Global access to antifungal therapy and its variable cost
Global access to antifungal therapy and its variable cost
复制标题
DOI：
10.1093/jac/dkw325
复制
发表时间：
2016-12-01
影响因子：
5.2
通讯作者：
Denning, David W.
中科院分区：
文献类型：
--
作者：
Kneale, Matthew;Bartholomew, Jennifer S.;Denning, David W.
背景：如果在危及生命的侵袭性感染早期给予抗真菌治疗，可以挽救生命，并极大地降低全球数亿患者的发病率。目的：我们按国家部分绘制了静脉注射脱氧胆酸两性霉素B(50 Mg)、氟胞嘧啶(5 G)、口服氟康唑(750-800 mg)和口服伊曲康唑(400 Mg)的系统性非专利抗真菌药物注册、可获得性和每日费用。方法：多种公共可用资源和当地国家联系人提供159个人口和GT国家的数据；结果：在155个国家中，有22个(14.2%)没有两性霉素B的许可，在155个国家中有42个国家(27.1%)没有两性霉素B的供应，这意味着未得到服务的人口为4.81亿。脱氧胆酸两性霉素B的每日价格从
Background: Antifungal therapy saves lives, if given early in life-threatening invasive infection, and also greatly reduces morbidity in hundreds of millions of patients worldwide.Objectives: We have partially mapped by country systemic generic antifungal drug registration, availability and daily cost for intravenous deoxycholate amphotericin B (50 mg), flucytosine (5 g), oral fluconazole (750-800 mg) and oral itraconazole (400 mg).Methods: Multiple publically available resources and local country contacts provided data for 159 countries with populations >1 million.Results: Amphotericin B is not licensed in and unavailable in 22 of 155 (14.2%) and 42 of 155 (27.1%) countries, respectively, representing an unserved population of 481 million. The daily price of deoxycholate amphotericin B varied from